AG
ANIK icon

Advisor Group’s Anika Therapeutics ANIK Stock Holding History

Advisor Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$27K Sell
522
-450
-46% -$26.1K ﹤0.01% 3793
2019
Q3 		$53K Buy
972
+352
+57% +$18.1K ﹤0.01% 3351
2019
Q2 		$25K Buy
620
+38
+7% +$1.39K ﹤0.01% 3824
2019
Q1 		$17K Buy
582
+49
+9% +$1.68K ﹤0.01% 4054
2018
Q4 		$18K Sell
533
-158
-23% -$5.7K ﹤0.01% 3860
2018
Q3 		$29K Buy
691
+38
+6% +$1.5K ﹤0.01% 3645
2018
Q2 		$21K Sell
653
-45
-6% -$1.85K ﹤0.01% 3676
2018
Q1 		$35K Sell
698
-277
-28% -$15.7K ﹤0.01% 3334
2017
Q4 		$52K Sell
975
-659
-40% -$36.5K ﹤0.01% 3051
2017
Q3 		$95K Buy
1,634
+137
+9% +$7.16K ﹤0.01% 2452
2017
Q2 		$74K Sell
1,497
-5
-0.3% -$230 ﹤0.01% 2547
2017
Q1 		$65K Buy
1,502
+1,170
+352% +$55.9K ﹤0.01% 2497
2016
Q4 		$16K Sell
332
-61
-16% -$2.82K ﹤0.01% 3346
2016
Q3 		$19K Sell
393
-76
-16% -$3.75K ﹤0.01% 3172
2016
Q2 		$24K Buy
+469
New +$22.1K ﹤0.01% 2944

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Advisor Group's ANIK Position: Q4 2019 in Review

Advisor Group reduced its Anika Therapeutics (ANIK) stake by 46% in Q4 2019, selling an estimated $26.1K and leaving 522 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #3793.

Advisor Group first reported a position in ANIK in Q2 2016 and has held it in 15 quarters since. The position peaked at $95K in Q3 2017. 191 funds tracked by Wall St. Rank hold ANIK as of Q4 2019.

  • Advisor Group held 522 shares of Anika Therapeutics worth $27K as of Q4 2019.
  • Advisor Group sold 450 Anika Therapeutics shares in Q4 2019, an estimated $26.1K.
  • Anika Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3793 holding.
  • Advisor Group first reported a position in Anika Therapeutics in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Anika Therapeutics position peaked at $95K in Q3 2017.
  • 191 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.